Guillain-Barre Syndrome Due to Tramadol
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 10 No. 4 (2020),
16 November 2020
,
Page 27146
https://doi.org/10.32598/ijmtfm.v10i4.27146
Abstract
Tramadol is a powerful prescription medication used for pain relief of varying intensities. Tramadol was initially produced in Germany to alleviate postsurgical and chronic pains. We describe a case of a 22-year-old male with no past medical history who took tramadol for the second time and then had a tonic-clonic seizure episode that worsened the weakness of his inferior limbs and followed by loss of consciousness. According to physical examination, clinical and paraclinical tests, he was diagnosed with Guillain-Barre syndrome. After treatment with intravenous immunoglobulin, he was improved and discharged 9 days after treatment. He was recommended to continue physiotherapy. The relation between tramadol using and Guillain-Barre syndrome development is unknown but it can be due to reactive oxygen species generation.
- Tramadol
- Gillian barre syndrome
- Reactive oxygen species
- Seizure
How to Cite
References
Rahimi HR, Soltaninejad K, Shadnia S. Acute tramadol poisoning and its clinical and laboratory findings. J Res Med Sci. 2014; 19(9):855-9. [PMID] [PMCID]
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43(13):879-923. [DOI:10.2165/00003088-200443130-00004] [PMID]
Nakamura A, Narita M, Miyoshi K, Shindo K, Okutsu D, Suzuki M, et al. Changes in the rewarding effects induced by tramadol and its active metabolite M1 after sciatic nerve injury in mice. Psychopharmacology (Berl) 2008; 200(3):307-16. [DOI:10.1007/s00213-008-1180-1] [PMID]
Rehni AK, Singh I, Kumar M. Tramadol-induced seizurogenic effect: A possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway. Basic Clin Pharmacol Toxicol. 2008; 103:262-6. [DOI:10.1111/j.1742-7843.2008.00276.x] [PMID]
Nagakannan P, Shivasharan BD, Thippeswamy BS, Veerapur VP. Effect of tramadol on behavioral alterations and lipid peroxidation after transient forebrain ischemia in rats. Toxicol Mech Methods. 2012; 22(9):674-8. [DOI:10.3109/15376516.2012.716092] [PMID]
Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; 2012(7):CD008943. [DOI:10.1002/14651858.CD008943.pub2] [PMID] [PMCID]
Gholami K, Shalviri G, Zarbakhsh A, Daryabari N, Yousefian S. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center. Pharmacoepidemiol Drug Saf. 2007; 16(2):229-37. [DOI:10.1002/pds.1331] [PMID]
Shadnia S, Soltaninejad K, Heydari K, Sasanian G, Abdollahi M. Tramadol intoxication: A review of 114 cases. Hum Exp Toxicol. 2008; 27(3):201-5. [DOI:10.1177/0960327108090270] [PMID]
Shadnia S, Brent J, Mousavi-Fatemi K, Hafezi P, Soltaninejad K. Recurrent seizures in tramadol intoxication: Implications for therapy based on 100 patients. Basic Clin Pharmacol Toxicol. 2012; 111(2):133-6. [DOI:10.1111/j.1742-7843.2012.00874.x] [PMID]
Hassanian-Moghaddam H, Farajidana H, Sarjami S, Owliaey H. Tramadol-induced apnea. Am J Emerg Med. 2013; 31(1):26-31. [DOI:10.1016/j.ajem.2012.05.013] [PMID]
Götrick B, Tobin G. The xerogenic potency and mechanism of action of tramadol inhibition of salivary secretion in rats. Arch Oral Biol. 2004; 49(12):969-73. [DOI:10.1016/j.archoralbio.2004.07.007] [PMID]
Rawal N, Macquaire V, Catalá E, Berti M, Costa R, Wietlisbach M. Tramadol/paracetamol combination tablet for postoperative pain following ambulatory hand surgery: A double-blind, double-dummy, randomized, parallel-group trial. J Pain Res. 2011; 4:103-10. [DOI:10.2147/JPR.S16760] [PMID] [PMCID]
Jovanović-Cupić V, Martinović Z, Nesić N. Seizures associated with intoxication and abuse of tramadol. Clin Toxicol (Phila) 2006; 44(2):143-6. [DOI:10.1080/1556365050014418] [PMID]
Le Berre JP, Desramé J, Lecoules S, Coutant G, Béchade D, Algayres JP. [Hyponatremia due to tramadol (French)]. Rev Med Interne. 2007; 28(12):888-9. [DOI:10.1016/j.revmed.2007.06.011] [PMID]
Wu WN, McKown LA, Liao S. Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica. 2002; 32(5):411-25. [DOI:10.1080/00498250110113230] [PMID]
Panchenko LF, Pirozhkov SV, Nadezhdin AV, Baronets VIu, Usmanova NN. [Lipid peroxidation, peroxyl radical-scavenging system of plasma and liver and heart pathology in adolescence heroin users (Russian)]. Vopr Med Khim. 1999; 45(6):501-6. [PMID]
Elmanama AA, Abu Tayyem NA, Esawwaf H, Hmaid I. Tramadol-induced liver and kidney toxicity among abusers in Gaza strip, Palestine. Jordan J Biol Sci. 2015; 8(2):133-7. [DOI:10.12816/0027559]
Savage R. Serious reactions with tramadol: Seizures and serotonin syndrome. New Zealand Medicines and Medical Devices Safety Authority. 2007; 28(1):11-3. https://www.medsafe.govt.nz/profs/puarticles/TramSerious.htm
Office of Communications and Public Liaison, National Institute of Neurological Disorders and Stroke, National Institutes of Health. Guillain-Barre syndrome fact sheet. Maryland: National Institute of Neurological Disorders and Stroke; 2016. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Guillain-Barr%C3%A9-Syndrome-Fact-Sheet
Ferri FF. Ferri’s Clinical Advisor 2017: 5 Books in 1. Amesterdam: Elsevier Health Sciences; 2016. https://www.amazon.com/Ferris-Clinical-Advisor-2017-Solutions/dp/032328048X
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334(8):494-500. [DOI:10.1056/NEJM199602223340803] [PMID]
Shin EJ, Jeong JH, Chung YH, Kim WK, Ko KH, Bach JH, et al. Role of oxidative stress in epileptic seizures. Neurochem Int. 2011; 59(2):122-37. [DOI:10.1016/j.neuint.2011.03.025] [PMID] [PMCID]
Aguiar CC, Almeida AB, Araújo PV, de Abreu RN, Chaves EM, do Vale OC, et al. Oxidative stress and epilepsy: Literature review. Oxid Med Cell Longev. 2012; 2012:795259. [DOI:10.1155/2012/795259] [PMID] [PMCID]
Ghabaee M, Jabedari B, Al-E-Eshagh N, Ghaffarpour M, Asadi F. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010; 120(4):301-4. [DOI:10.3109/00207451003695690] [PMID]
Kumar KT, Chandrika A, Sumanth KN, Sireesha P, Rao S, Rao A. Free radical toxicity and antioxidants in Guillain-Barre syndrome, A preliminary study. Clin Chim Acta. 2004; 346(2):205-9. [DOI:10.1016/j.cccn.2004.03.032] [PMID]
Sheweita SA, Almasmari AA, El-Banna SG. Tramadol-induced hepato- and nephrotoxicity in rats: Role of Curcumin and Gallic acid as antioxidants. PLoS One. 2018; 13(8):e0202110. [DOI:10.1371/journal.pone.0202110] [PMID] [PMCID]
Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, metabolism, and misuse. Anesth Analg. 2017; 124(1):44-51. [DOI:10.1213/ANE.0000000000001683] [PMID]
Dean L. Tramadol Therapy and CYP2D6 Genotype. In: Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, et al., (editors). Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. [PMID]
Arafa MH, Atteia HH. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity. Toxicol Appl Pharmacol. 2018; 346:37-44. [DOI:10.1016/j.taap.2018.03.019] [PMID]
Raffa RB. Basic pharmacology relevant to drug abuse assessment: Tramadol as example. J Clin Pharm Ther. 2008; 33(2):101-8. [DOI:10.1111/j.1365-2710.2008.00897.x] [PMID]
- Abstract Viewed: 854 times
- pdf Downloaded: 444 times